Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. MASLD is most often covered alongside Cannabis, which appears in 1 of these 1 story. At 6, the average consequence score sits above the same-window beat average of 5.9.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. MASLD is most often covered alongside Cannabis, which appears in 1 of these 1 story. At 6, the average consequence score sits above the same-window beat average of 5.9. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. MASLD appears in 1 tracked Healthcare story from March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MASLD. Shared-story counts are live from our verified record — not editorial picks.
Emerging clinical research indicates that specific cannabis-derived compounds may reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition affecting nearly 33% of the global adult population. This discovery could shift the treatment paradigm for a disease that currently has few FDA-approved pharmacological interventions.
Source: fox10phoenix.com · fox35orlando.com
MASLD is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
